• Revenue Growth: Q4 worldwide revenue increased by 2% year-over-year to $116.2 million; full-year revenue up 5% to $425.2 million.

• Net Loss Improvement: Q4 net loss from operations narrowed to $11.8 million from $19.4 million in the prior year; full-year net loss was $99.3 million.

• Adjusted EBITDA: Q4 adjusted EBITDA turned positive at $8.4 million; full-year adjusted EBITDA loss improved to $17.7 million from $23.8 million in 2022.

• Strategic Acquisitions and Restructuring: Acquisition of Vyrsa Technologies and a workforce reduction aimed at long-term growth and profitability.

• 2024 Outlook: Full-year 2024 revenue projected to grow 2% to 5%, with adjusted EBITDA loss expected to narrow.

• Warning! GuruFocus has detected 3 Warning Signs with NVRO.

Nevro Corp (NYSE:NVRO) released its 8-K filing on February 21, 2024, detailing its fourth-quarter and full-year 2023 financial results and providing guidance for the full-year and first-quarter of 2024. The company, known for its HFX spinal cord stimulation (SCS) platform for chronic pain treatment, has shown a modest increase in revenue amidst strategic changes aimed at long-term profitability.

Financial Performance and Strategic Developments

In Q4 2023, Nevro saw worldwide revenue grow to $116.2 million, a 2% increase both reported and on a constant currency basis compared to the same period in 2022. This growth was partly driven by a 29% increase in sales for the Painful Diabetic Neuropathy (PDN) Indication, which amounted to approximately $22.4 million. Despite a slight decrease in U.S. trial procedures, U.S. PDN trial procedures made up 24% of total U.S. trials, reflecting a 17% growth over the previous year's quarter.

The company's gross profit for the quarter was $81.5 million, with a gross margin of 70.1%, up from 66.1% in Q4 2022. This improvement was primarily due to a shift to higher margin products and reduced scrap-related charges. Operating expenses decreased slightly to $93.3 million, with a notable $3.0 million one-time expense related to the Vyrsa acquisition.

Nevro's net loss from operations for Q4 2023 was $11.8 million, an improvement from a net loss of $19.4 million in the same period the previous year. The adjusted EBITDA for the quarter was a positive $8.4 million, a significant turnaround from a loss of $1.4 million in Q4 2022.

For the full year of 2023, Nevro reported a worldwide revenue of $425.2 million, a 5% increase over the previous year. The full-year net loss from operations was $99.3 million, compared to a net income from operations of $6.2 million in 2022, which included significant litigation-related credits. The adjusted EBITDA loss for the full year improved to $17.7 million from $23.8 million in 2022.